Vitti Long Haul Stem Cell Research Clinical Trials focus on developing innovative treatments for Pulmonary Fibrosis in Long Haul COVID patients. The combination therapy of VL-PX10 and VL-P22 uses Umbilical Cord Mesenchymal Stem Cell Exosomes and Stem Cells to promote tissue regeneration and healing. Currently in Phase 2 trials, this therapy shows promise in aiding the recovery of patients with COVID-related respiratory issues.